Mera Pharmaceuticals, Inc.
MRPI · OTC
10/31/2011 | 7/31/2011 | 4/30/2011 | 1/31/2011 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.18 | -0.00 | 0.09 |
| FCF Yield | -6.53% | 0.24% | -0.40% | 0.09% |
| EV / EBITDA | -10.85 | -75.35 | -40.21 | -33.79 |
| Quality | ||||
| ROIC | 11.59% | 2.31% | 4.92% | 5.46% |
| Gross Margin | 96.51% | 99.67% | 88.30% | 94.53% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -20.36% | -22.70% | -26.82% | -27.23% |
| Free Cash Flow Growth | -2,733.82% | 147.99% | -649.76% | 100.72% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | -3.01 | -1.38 | -1.33 |
| Interest Coverage | -50.10 | -16.08 | -39.15 | -25.87 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -19,583.64 | -47,520.53 | -1,309.84 | -3,804.57 |